Pharmaceutical Executive-06-01-2016

Pharm Exec’s 16th annual listing of the top biopharma players may look placid on the surface, but, upon deeper inspection, does point to important transitions taking place in the larger business model.

Biopharma’s diversity commitment remains a work in progress but the benefits-in measurable ROI-are increasingly clear.

A new industry working group explores alternative drug funding options in Europe-and asks key stakeholders in the region to join the discussion.

Pharm Exec explores the power of workplace aesthetic on the intangibles of culture, morale-and corporate mission-in a visit to one big Pharma's unique US headquarters.

How companies can better integrate valuable data across business functions to meet rising value-chain demands.

A new educational and potential prognosis tool for the treatment of multiple sclerosis shows how an accessible, easy-to-see visualization of disease state can serve as the threshold for fresh clinical insight-all geared to the individual patient.

Do recent trends in the pharma and biotech M&A and equity markets signal a temporary lull - or a permanent drop? Peter Young reports.

There’s a stampede to relate prices to broader health benefits, but little consensus on how to do so, writes Jill Wechsler.

Top officials at EMA push the boat out on drug-pricing views.

While the Italian fashion and automotive industries may steal the global thunder, another sector in Italy flourishes beneath the public’s radar. The country’s pharmaceutical industry continues to punche above its weight in many areas and has supported Italy’s national economy through many periods of weakness.

Click the title above to open the Pharmaceutical Executive June 2016 issue in an interactive PDF format.